Nesiritide in acute decompensated heart failure: Current status and future perspectives

Reviews in Cardiovascular Medicine

Volumn 9, Issue 3, 2008, Pages 151-158

  Mohammed, Selma F ^a   Korinek, Josef ^a,b   Chen, Horng H ^a   Burnett, John C ^a   Redfield, Margaret M ^a  

^a MAYO CLINIC   (United States)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Acute decompensated heart failure; B type natriuretic peptide; Nesiritide; Renal function

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; GLYCERYL TRINITRATE; NESIRITIDE; NEUROHORMONE; NITROPRUSSIDE SODIUM; PLACEBO; VASODILATOR AGENT;

CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEART FAILURE; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MORTALITY; NEPHROTOXICITY; RECOMMENDED DRUG DOSE; REVIEW; SYMPTOM; TREATMENT INDICATION; TREATMENT OUTCOME;

ACUTE DISEASE; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DRUG COSTS; HEART FAILURE; HUMANS; HYPERTENSION; KIDNEY; NATRIURETIC PEPTIDE, BRAIN; PATIENT SELECTION; RISK ASSESSMENT; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 53949088681     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005; 112:3958-3968.
2. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25-e146.
3. Heart Failure Society of America. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006; 12:10-38.
4. Teerlink JR. Overview of randomized clinical trials in acute heart failure syndromes. Am J Cardiol. 2005;96:59G-67G.
5. Redfield MM. Understanding "diastolic" heart failure. N Engl J Med. 2004;350:1930-1931.
6. Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47:1987-1996.
7. Abraham WT, Adams KF, Fonarow GC, et al. Inhospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46:57-64.
8. Lam CS, Burnett JC Jr, Costello-Boerrigter L, et al. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol. 2007; 49:1193-1202.
9. Munagala VK, Burnett JC Jr, Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol. 2004;29:707-769.
10. Januzzi JL Jr, Chen-Tournoux AA, Moe G. Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol. 2008;101:29-38.
11. Hawkridge AM, Heublein DM, Bergen HR 3rd, et al. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA. 2005;102:17442-17447.
12. Shimizu H, Masuta K, Aono K, et al. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta. 2002;316:129-135.
13. Shimizu H, Masuta K, Asada H, et al. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta. 2003;334:233-239.
14. Apple FS, Panteghini M, Ravkilde J, et al. Quality specifications for B-type natriuretic peptide assays. Clin Chem. 2005;51:486-493.
15. Heublein DM, Boerrigter G, Cataliotti A, et al. Differential biological actions and assay detection of altered forms of NBNP in vitro [abstract]. J Card Fail. 2006;12(suppl 1):S29.
16. Brandt I, Lambeir AM, Ketelslegers JM, et al. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem. 2006;52:82-87.
17. Boerrigter G, Costello-Boerrigter LC, Harty GJ, et al. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol. 2007;292:R897-R901.
18. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 1991;84:1581-1588.
19. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996;94:3184-3189.
20. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998;4:37-44.
21. Hobbs RE, Miller LW, Bott-Silverman C, et ai. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemie or idiopathic dilated cardiomyopathy. Am J Cardiol. 1996;78:896-901.
22. Mills RM, Lejemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol. 1999, 34:155-162.
23. Colucd WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343:246-253.
24. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540.
25. Elkayam U, Akhter MW, Singh H, et al. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. Am J Cardiol. 2004, 93:237-240.
26. Peacock WF 4th, Holland R, Gyarmathy R, et al. Observation unit treatment of heart failure with nesiritide: results from the proaction trial. J Emerg Med. 2005;29:243-252.
27. Burger AJ, Horton DP, Lejemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J. 2002;144:1102-1108.
28. Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on shortterm outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol. 2002, 39:798-803.
29. Chen HH, Burnett JC Jr. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians. 1999;111:406-416.
30. Nesiritide. Physician's Desk Reference. 58th ed. Montvale, NJ: Thompson PDR; 2004:335.
31. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-491.
32. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293.1900-1905.
33. Wang DJ, Dowling TC, Meadows D, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation. 2004;110:1620-1625.
34. Owan TE, Chen HH, Frantz RP, et al. The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction. J Card Fail. 2008, 14:267-275.
35. Witteles RM, Kao D, Christopherson D, et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol. 2007;50:1835-1840.
36. Yancy CW, Saltzberg MT, Berkowitz RL, et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION 1 trial). Am J Cardiol. 2004;94:S95-601.
37. Yancy CW, Krum H, Massie BM, et al for the FUSION II Investigators. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. Circ Heart Fail. 2008;1:9-16.
38. Burnett JC Jr, Korinek J. The tumultuous journey of nesiritide: past, present and future. Circ Heart Fail. 2008;1:6-8.
39. Riter HG, Redfield MM, Burnett JC, Chen HH. Nonhypotensive low-dose nesiritide has differential renal effects compared with standarddose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol. 2006;47:2334-2335.
40. Mentzer RM Jr, Oz MC, Sladen RN, et al. Effects of perioperattve nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA Trial. J Am Coll Cardiol. 2007; 49:716-726.
41. Chen HH, Sundt TM, Cook DJ, et al. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study. Circulation. 2007, 116(11 suppl):I134-I138.
42. Arora RR, Venkatesh PK, Molnar J. Short and long-term mortality with nesiritide. Am Heart J. 2006;152:1084-1090.
43. Topol EJ. Nesiritide-not verified. N Engl J Med. 2005;353:113-116.
44. Hauptman PJ, Schnitzler MA, Swindle J, Burroughs TE. Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure. JAMA. 2006;296:1877-1884.
45. de Lissovoy G, Stier DM, Ciesla G, et al. Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure. Am J Cardiol. 2003;92:631-633.
46. Gerhard T, Zineh I, Winterstein AG, Hartzema AG. Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure. Pharmacotherapy. 2006;26:34-43.
47. Lewis DA, Gurram NR, Abraham WT, Akers WS. Effect of nesiritide versus milrinone in the treatment of acute decompensated heart failure. Am J Health Syst Pharm. 2003;60(suppl 4): S16-S20.
48. Chen HH, Redfield MM, Nordstrom LJ, et al. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail 2004, 10:115-119.
49. Wang W, Ou Y, Shi Y. Albu BNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. Pharm Res. 2004;21:2105-2111.
50. Cataliotti A, Chen HH, James KD, Burnett JC Jr. Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease. Trends Cardmasc Med. 2007;17:10-14.
51. Korinek J, Boerrigter G, Mohammed SF, Burnett JC Jr. Insights into natriuretic peptides in heart failure: an update. Curr Heart Fail Rep. 2008; 5:97-104.